Form 4: Altimmune Director Granted 48,800 Stock Options

Altimmune, Inc. Director Jerome Benedict Durso was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Summary

• Jerome Benedict Durso, a Director of Altimmune, Inc. (ALT), was granted 48,800 stock options.
• The transaction date for this acquisition of derivative securities was September 25, 2025.
• Each option has an exercise price of $3.92.
• The options will vest and become exercisable in substantially equal monthly installments over 12 months, starting from September 25, 2025.
• Vesting is contingent upon Mr. Durso's continued service to the company through the applicable vesting dates.
• The expiration date for these stock options is September 25, 2035.
• Following this transaction, Mr. Durso beneficially owns 48,800 derivative securities directly.

Sentiment

Score: 7

Explanation: The filing indicates a routine compensation event for a director, which is generally positive for corporate governance and alignment of interests, but does not contain information that would significantly alter the company's fundamental outlook or valuation.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• This is a standard practice for director compensation, indicating a routine governance activity.

Future Outlook

The vesting schedule of the stock options over 12 months implies an expectation of continued service from the director, aligning their future contributions with the company's performance.

Industry Context

The grant of stock options to directors is a common compensation strategy in the biotechnology and pharmaceutical industries, aiming to attract and retain experienced leadership while linking their rewards to the company's stock performance.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a widely accepted practice across various industries, including biotech, to align leadership incentives with shareholder value creation.
• The vesting schedule over 12 months is a typical short-to-medium term incentive structure, comparable to similar grants observed in companies like Moderna or BioNTech for their non-executive directors, though the specific number of options and exercise price would vary based on company size, stock price, and compensation philosophy.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing stock value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest in monthly installments over the 12 months following September 25, 2025, subject to continued service.

Key Dates

Recommendation

A Form 4 filing primarily discloses insider transactions and does not provide sufficient fundamental or strategic information to warrant a 'buy' or 'sell' recommendation. This specific filing details a routine stock option grant to a director, which is a standard compensation practice aimed at aligning interests, and does not indicate a significant change in the company's outlook or valuation. Investors should consider this as a normal course of business disclosure.

Keywords

Altimmune, ALT, Stock Options, Director Compensation, Form 4, Insider Transaction, Equity Grant, Jerome Durso